Lundbeck
PharmaCopenhagen, Denmark, Denmark · Est. 1915 · 8,200 employees
Lundbeck is a Danish pharmaceutical company focused on developing and commercializing innovative treatments for psychiatric and neurological disorders.
3
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
5
Indications↗
Distinct diseases across all programs
246
Clinical Trials↗
All sponsored trials (all statuses)
6
Orange Book Patents
Across 2 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
3 drugs in development
Phase 22
Phase 12
By Therapeutic Area
top 3
Metabolic & Endocrine
240%
Ophthalmology
240%
Neurology
120%
R&D Momentum
56/100
Pipeline Velocity
19/100
Trial Completion Rate
81/100
Pipeline Concentration
36/100
Pipeline Freshness
75/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity
Activity
Key Events
Oct 17, 2026TrialInterventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 Years) for the Preventive Treatment of Chronic Migraine
Oct 17, 2026TrialA Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease
Oct 15, 2026TrialLong-term, Open-label (Dose-blinded), Extension Study of Eptinezumab in Children and Adolescents With Chronic or Episodic Migraine
Oct 15, 2026TrialInterventional, Randomized, Double-blind, Placebo-controlled, Optional Open-label Extension Trial of Lu AF82422 in Participants With Multiple System Atrophy
Oct 15, 2026TrialInterventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 Years) for the Preventive Treatment of Episodic Migraine
Oct 15, 2026TrialInterventional, Open-label, Fixed-sequence Crossover Trial Investigating the Effect of CYP3A4/5 Modulation on the Pharmacokinetics, Safety and Tolerability of Lu AH69593 and the Effect of Lu AH69593 on the Pharmacokinetics of a CYP3A4/5 Substrate in Healthy Participants
Oct 6, 2026TrialInterventional, Open-label, Extension Trial of Asedebart (Lu AG13909) in Participants With Congenital Adrenal Hyperplasia
Sep 10, 2026TrialInterventional, Open-label, Single-group, Long-term Follow-up Trial of Lu AG22515 in Patients With Moderate-to-severe Thyroid Eye Disease
4 more events
Sep 10, 2026TrialInterventional, Open-label Trial, Investigating the Effectiveness of Eptinezumab in Participants With Migraine and Previous Inadequate Response to CGRP-targeting Therapies
Sep 9, 2026TrialInterventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Trial of Lu AF28996 in Adults With Parkinson's Disease Experiencing Motor Fluctuations
Aug 13, 2026TrialInterventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single- and Multiple-ascending-dose Trial Investigating Safety, Tolerability, and Pharmacokinetics of Lu AH69593 in Healthy Participants, Including Open-label Cohorts to Explore Pharmacodynamic Properties in Participants With Narcolepsy, and Food Effect in Healthy Participants
Aug 11, 2026TrialInterventional, Open-label, Trial Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF28996 in Chinese Men and Women With Parkinson's Disease
Details
Company Info
Company Overview
$9.5B
Mkt Cap
$2.2B
Revenue
—
Cash
CEODeborah Dunsire
Founded1915
Employees8,200
HQCopenhagen, Denmark, Denmark
Websitelundbeck.com
LinkedInCompany Page
Therapeutic Focus
psychiatryneurologypain managementaddiction
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Ophthalmology
Metabolic & Endocrine
Cushing's Disease
Lu AF95245Phase 2
Lu AG13909Phase 2
Neurology
Migraine
Lu AF95245Phase 2
Ophthalmology
Thyroid Eye Disease
Lu AF95245Phase 1
Lu AG22515Phase 1
Regulatory
Regulatory Timeline
20121 event
FDADec 14
Sympazan — ONFI
Application NDA203993 (NDA)
20144 events
FDANov 3
Northera — NORTHERA
Application NDA203202
FDASep 30
Northera — NORTHERA
Application NDA203202
FDAFeb 18
Northera — NORTHERA
Application NDA203202 (NDA)
FDAFeb 18
Northera — NORTHERA
Application NDA203202
20152 events
FDAAug 24
Northera — NORTHERA
Application NDA203202
FDAAug 19
Northera — NORTHERA
Application NDA203202
20161 event
FDAOct 3
Northera — NORTHERA
Application NDA203202
20171 event
FDAFeb 10
Northera — NORTHERA
Application NDA203202
20181 event
FDANov 1
Sympazan — SYMPAZAN
Application NDA210833 (NDA)
20202 events
FDAFeb 21
Vyepti — VYEPTI
Application BLA761119
FDAFeb 21
Vyepti — VYEPTI
Application BLA761119 (BLA)
20211 event
FDASep 24
Vyepti — VYEPTI
Application BLA761119
20221 event
FDAOct 21
Vyepti — VYEPTI
Application BLA761119
20241 event
FDAJun 17
Sabril — VIGAFYDE
Application NDA217684 (NDA)
20254 events
FDAOct 22
Vyepti — VYEPTI
Application BLA761119
FDAAug 18
Vyepti — VYEPTI
Application BLA761119
FDAMar 21
Vyepti — VYEPTI
Application BLA761119
FDAMar 21
Vyepti — VYEPTI
Application BLA761119
20261 event
FDAJun 5
Vyepti — VYEPTI
Application BLA761119
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)